Objective: Medication non-adherence is frequently reported in patients with major depressive disorder (MDD). The objective of this review is to consolidate data on the prevalence of non-adherence to ...

Abstract: With the intensification of population aging and the increasing number of chronic disease patients, the problem of missed or incorrect medication among the elderly due to memory decline has ...

Trapped in a hell he helped make, a lone hacker aboard a space station far from home sneaks and fights his way through horrible mutants and killer robots in order to take down the monstrous artificial ...

SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading Singapore-based maritime electrification startup, has secured S$13 million in the first close of its S$18 million growth ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...

Pyxis’ team. Photo source: Singapore Maritime Foundation. Bringing you the latest updates on funding and investment activity across the Asia Pacific. Pyxis raises SGD 13 million to drive maritime ...